Please login to the form below

Not currently logged in
Email:
Password:

Pharma wants review of EMA pharmacovigilance fees

EFPIA among associations to call for ‘balanced and transparent’ funding
EU flag

The pharmaceutical industry has called on the European Medicines Agency (EMA) to re-assess the way it handles pharmacovigilance payments to make them more "balanced and transparent".

The European Federation of Pharmaceutical Industries and Associations (EFPIA) was one of several industry organisations to say they were concerned about the "increasing financial burden" for companies who pay into the system to assess the safety of medicines approved in the EU.

These payments apply to the marketing authorisation holder for any drug licensed by the EMA and have been in place since the EU adopted new pharmacoviglance legislation in 2010.

A joint statement from EFPIA and the European Generic medicines Association (EGA), European biotech industry (EuropaBio), Association of the European Self-Medication Industry (AESGP) and European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), voiced its support for the "implementation of an effective pharmacovigilance system to ensure patient safety".

The groups said they recognised "recent efforts which have been made to ensure greater fairness, proportionality and transparency", but said further revision of the payment process was needed.

This was especially pressing for procedural fees, such as for pharmacovigilance referrals, which have significantly increased compared to calculations from 2008 in a process 'without open and transparent communication'.

To remedy this the industry wants annual cost breakdowns, along with detailed information on performance indicators, to be presented for the activities covered by the fees regime.

This would tie in with EMA efforts to improve transparency in other areas, including posting minutes for its committee meetings.

These issues are likely to be discussed further during overall legislative revision of the EMA fees regime, which is expected at some point during the year.

One potential solution offered by the industry groups in their statement included sharing the cost of pharmacovigilance activities beyond drug companies due to the public health importance of medicines safety.

Article by
Thomas Meek

25th February 2014

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
nitrogen

nitrogen is a strategic brand experience agency which blends science and imagination; delivering multi-channel communications that are both compelling and...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics